<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Korean J Physiol Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Korean J. Physiol. Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">KJPP</journal-id>
<journal-title-group>
<journal-title>The Korean Journal of Physiology &amp; Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1226-4512</issn>
<issn pub-type="epub">2093-3827</issn>
<publisher>
<publisher-name>The Korean Physiological Society and The Korean Society of Pharmacology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32140036</article-id>
<article-id pub-id-type="pmc">7043995</article-id>
<article-id pub-id-type="doi">10.4196/kjpp.2020.24.2.129</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Connecting the dots between SHP2 and glutamate receptors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ryu</surname>
<given-names>Hyun-Hee</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Sun Yong</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lee</surname>
<given-names>Yong-Seok</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Physiology, Seoul National University College of Medicine, Seoul 03080, <country>Korea</country>.</aff>
<aff id="A2"><label>2</label>Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, <country>Korea</country>.</aff>
<aff id="A3"><label>3</label>Neuroscience Research Institute, Seoul National University College of Medicine, Seoul 03080, <country>Korea</country>.</aff>
<author-notes>
<corresp>Correspondence: Yong-Seok Lee. <email>yongseok7@snu.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<issue>2</issue>
<fpage>129</fpage>
<lpage>135</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>06</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© Korean J Physiol Pharmacol</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>The Korean Physiological Society and The Korean Society of Pharmacology</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>SHP2 is an unusual protein phosphatase that functions as an activator for several signaling pathways, including the RAS pathway, while most other phosphatases suppress their downstream signaling cascades. The physiological and pathophysiological roles of SHP2 have been extensively studied in the field of cancer research. Mutations in the <italic>PTPN11</italic> gene which encodes SHP2 are also highly associated with developmental disorders, such as Noonan syndrome (NS), and cognitive deficits including learning disabilities are common among NS patients. However, the molecular and cellular mechanism by which SHP2 is involved in cognitive functions is not well understood. Recent studies using SHP2 mutant mice or pharmacological inhibitors have shown that SHP2 plays critical role in learning and memory and synaptic plasticity. Here, we review the recent studies demonstrating that SHP2 is involved in synaptic plasticity, and learning and memory, by the regulation of the expression and/or function of glutamate receptors. We suggest that each cell type may have distinct paths connecting the dots between SHP2 and glutamate receptors, and these paths may also change with aging.</p>
</abstract>
<kwd-group>
<kwd>AMPA receptor</kwd>
<kwd>Learning and memory</kwd>
<kwd>NMDA receptor</kwd>
<kwd>Rasopathy</kwd>
<kwd>Synaptic plasticity</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Research Foundation of Korea</institution>
<institution-id institution-id-type="CrossRef">https://doi.org/10.13039/501100003725</institution-id>
</institution-wrap>
</funding-source>
<award-id>NRF-2019R1A2C1084232</award-id>
<award-id>NRF-2019R1A4A2001609</award-id>
<award-id>NRF-2019R1A6A3A01097089</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>SHP2 is a non-receptor protein tyrosine phosphatase encoded by the <italic>PTPN11</italic> gene which is located on chromosome 12q in humans [<xref ref-type="bibr" rid="B1">1</xref>]. The human <italic>PTPN11</italic> gene was first cloned from a human umbilical cord cDNA library and originally named <italic>PTP2C</italic> [<xref ref-type="bibr" rid="B2">2</xref>]. SHP2 contains two SH2 domains (an N-terminal and a C-terminal SH2 domain) at its N-terminus, which are followed by a protein tyrosine phosphatase (PTP) domain [<xref ref-type="bibr" rid="B2">2</xref>]. Shortly after cloning, the crystal structure of SHP2 was revealed [<xref ref-type="bibr" rid="B3">3</xref>]. In the basal state, the N-terminal SH2 domain interacts with the PTP domain and prevents the catalytic domain from accessing the substrate [<xref ref-type="bibr" rid="B3">3</xref>]. Binding of the N-terminal SH2 domain (N-SH2) to a phosphopeptide triggers a conformational change in SHP2 and releases auto-inhibition by N-SH2, suggesting that the N-SH2 functions as a molecular switch [<xref ref-type="bibr" rid="B3">3</xref><xref ref-type="bibr" rid="B4">4</xref>]. Phosphorylated receptor tyrosine kinases and adaptor proteins, such as GRB2, serve as upstream activators for SHP2 [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref>]. SHP2 harbors two tyrosine phosphorylation sites (Y542 and Y580) of which phosphorylation can affect its activity upon stimulation with several growth factors [<xref ref-type="bibr" rid="B7">7</xref>]. Activation mechanisms of SHP2 might differ in different tissue and cell types, which remain to be further investigated. SHP2 is required for the full activation of the RAS-MAPK signaling pathway [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref><xref ref-type="bibr" rid="B8">8</xref>]. Either inhibiting activity or expression of SHP2 was shown to reduce RAS-MAPK activity in response to some, but not all, growth factors [<xref ref-type="bibr" rid="B9">9</xref><xref ref-type="bibr" rid="B10">10</xref>]. Accordingly, loss-of-function SHP2 mutations (Y279C, A461T, T468M, G464A) found in LEOPARD syndrome showed reduced catalytic activity as well as reduced MAPK activation compared to those of wild type SHP2 in response to EGF treatment in HEK293T cell [<xref ref-type="bibr" rid="B10">10</xref>]. Consistently, heart lysates from knock-in mice expressing a LEOPARD syndrome associated SHP2 Y297C mutation showed reduced ERK activation [<xref ref-type="bibr" rid="B11">11</xref>]. However, it is puzzling that MAPK activation was found to be increased in both a patient-derived iPSC (SHP2 T468M) and a zebrafish model (SHP2 A462T) of LEOPARD syndrome [<xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B13">13</xref>]. The reason for the discrepancy between <italic>in vitro</italic> and <italic>in vivo</italic> experiments is not clear [<xref ref-type="bibr" rid="B14">14</xref>]. In addition to the RAS pathway, SHP2 has also been shown to activate the PI3K-AKT pathway, while it inhibits the JAK-STAT pathway [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B15">15</xref><xref ref-type="bibr" rid="B16">16</xref><xref ref-type="bibr" rid="B17">17</xref>]. The detailed molecular roles of SHP2 in signaling cascades have been extensively reviewed elsewhere [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>Mutations in <italic>PTPN11</italic> are associated with developmental disorders including Noonan syndrome (NS) and LEOPARD syndrome [<xref ref-type="bibr" rid="B10">10</xref><xref ref-type="bibr" rid="B18">18</xref>]. Gain-of-function mutations in <italic>PTPN11</italic> are associated with NS, while loss-of-function mutations are associated with LEOPARD syndrome [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref><xref ref-type="bibr" rid="B10">10</xref>]. Interestingly, there are many overlapping features between NS and LEOPARD syndrome including developmental delays and learning difficulties [<xref ref-type="bibr" rid="B14">14</xref>]. It is not clear how the mutations resulting in opposite effects on the same signaling pathway can cause a similar phenotype. However, it is not unique to <italic>PTPN11</italic> mutations that both overexpression and suppression of a particular gene result in the overlapping phenotypes by disrupting the fine-tuned regulation of the corresponding signaling network. For example, both loss- and gain-of-functions of <italic>MeCP2</italic> in mice were shown to cause similar hippocampal circuit dysfunction [<xref ref-type="bibr" rid="B19">19</xref>]. Alternatively, one possible mechanism for this paradox is that LEOPARD syndrome associated loss-of-function <italic>PTPN11</italic> mutations result in MAPK activation, not inactivation, by unknown mechanisms as mentioned above [<xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B13">13</xref>].</p>
<p><italic>PTPN11</italic> mutations also induce cancers but, interestingly, mutations in cancer do not overlap with those in NS while mutations in both conditions commonly result in hyperactivation of the RAS-MAPK signaling pathway in most of the cases [<xref ref-type="bibr" rid="B20">20</xref>]. NS is a relatively common developmental disorder inherited in an autosomal dominant pattern and <italic>PTPN11</italic> mutations account for 40%â50% of cases [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref><xref ref-type="bibr" rid="B20">20</xref>]. The expressivity of NS is quite diverse and patients show a wide range of phenotypes including short stature, congenital heart deficits, typical craniofacial phenotypes, and various cognitive symptom [<xref ref-type="bibr" rid="B20">20</xref><xref ref-type="bibr" rid="B21">21</xref>]. Not much attention has been paid to the cognitive features in NS compared to physical phenotypes. Recently, multiple studies have shown that cognitive problems, such as learning and memory impairments and social problems which substantially affect the quality of life, are relatively common among NS patients [<xref ref-type="bibr" rid="B22">22</xref><xref ref-type="bibr" rid="B23">23</xref><xref ref-type="bibr" rid="B24">24</xref>]. Studies using animal models can provide in-depth understanding of the molecular and cellular mechanism underlying cognitive deficits in genetic disorders [<xref ref-type="bibr" rid="B25">25</xref><xref ref-type="bibr" rid="B26">26</xref><xref ref-type="bibr" rid="B27">27</xref>]. There are multiple animal models of NS from fly to mouse [<xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B18">18</xref><xref ref-type="bibr" rid="B28">28</xref><xref ref-type="bibr" rid="B29">29</xref><xref ref-type="bibr" rid="B30">30</xref>]. In this mini review, we will review the learning and memory phenotypes in NS mouse models and recent studies investigating the role of SHP2 in synaptic plasticity, with a specific emphasis on its regulation of glutamate receptors.</p>
</sec>
<sec>
<title>IMPAIRED LEARNING AND SYNAPTIC PLASTICITY IN Shp2 MUTANT MICE</title>
<p>In order to study the biological mechanism for the cognitive deficits in NS, several animal models have been generated. Pagani and colleagues [<xref ref-type="bibr" rid="B28">28</xref>] showed that flies expressing a constitutively active mutant Shp2 (<italic>csw</italic>) showed long-term memory deficits, which was one of the first reports demonstrating that Shp2 mutant animals display memory deficits. Mutant mice have been widely used as animal models of NS and other Rasopathies (for review, see [<xref ref-type="bibr" rid="B25">25</xref><xref ref-type="bibr" rid="B29">29</xref>]). Shp2<sup>D61G/+</sup> knock-in mice expressing a NS-associated gain-of-function mutant Shp2 showed phenotypes which are similar to typical symptoms of NS such as short stature and heart defects [<xref ref-type="bibr" rid="B18">18</xref>]. Shp2<sup>D61G/+</sup> mice showed deficits in hippocampal learning and memory [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B32">32</xref>]. Another knock-in mouse model expressing the most common NS allele Shp2<sup>N308D/+</sup> also has impaired spatial learning and memory, albeit with a weaker phenotype than that seen in Shp2<sup>D61G/+</sup> mice [<xref ref-type="bibr" rid="B31">31</xref>]. Memory deficits in Shp2<sup>D61G/+</sup> mice can be reversed by reducing Erk activity in adult mice, suggesting that the increased activation of the Ras-Erk signaling pathway is responsible for the memory deficits in the mutant mice [<xref ref-type="bibr" rid="B31">31</xref>]. Interestingly, a recent study showed that overexpressing the mutant Shp2<sup>D61G</sup> only in hippocampal excitatory neurons, but not in inhibitory neurons, can induce spatial memory deficits in mice [<xref ref-type="bibr" rid="B33">33</xref>]. Synaptic plasticity is considered as a cellular mechanism of higher cognitive functions including learning and memory [<xref ref-type="bibr" rid="B34">34</xref><xref ref-type="bibr" rid="B35">35</xref><xref ref-type="bibr" rid="B36">36</xref><xref ref-type="bibr" rid="B37">37</xref>]. Consistently, both Shp2<sup>D61G/+</sup> and Shp2<sup>N308D/+</sup> models show significant deficits in long-term potentiation (LTP) in the hippocampal Schaffer-collateral (CA3-CA1) pathway, which can be also reversed by reducing Erk activation [<xref ref-type="bibr" rid="B31">31</xref>], strongly suggesting that LTP deficits may underlie the memory deficits in NS.</p>
<p>The role of Shp2 in memory and synaptic plasticity has also been examined in a conditional knockout mouse in which Shp2 is specifically deleted in the forebrain using Î±CaMKII-CRE [<xref ref-type="bibr" rid="B38">38</xref>]. The conditional knockout mice exhibited a mild deficit in spatial learning in the Morris water maze task [<xref ref-type="bibr" rid="B38">38</xref>]. Basal synaptic transmission and post-tetanic potentiation at CA3-CA1 synapse are significantly reduced, but hippocampal LTP is normal in the knockout mice [<xref ref-type="bibr" rid="B38">38</xref>], suggesting that Shp2 is required for normal synaptic transmission and short-term synaptic plasticity in the hippocampus. Interestingly, another conditional Shp2 knockout mouse line (Î±CaMKII-Cre: Shp2<sup>flox/flox</sup> or CaSKO), in which Shp2 is also deleted by Î±CaMKII-Cre, showed deficits in long-term fear memory tested 7 days after training, whereas recent memory tested 1 day after training was intact [<xref ref-type="bibr" rid="B39">39</xref>]. Furthermore, this knockout showed significant impairment in hippocampal LTP [<xref ref-type="bibr" rid="B39">39</xref>]. The discrepancy between these two knockout mice might stem from differences in either deleted exons (exon 4 or 11) or the CRE lines used in each study [<xref ref-type="bibr" rid="B40">40</xref><xref ref-type="bibr" rid="B41">41</xref>]. Studies using Shp2 knockout and Shp2 knock-in mice reviewed here demonstrate that Shp2 is critically involved in learning and memory, as well as synaptic plasticity. But what is the mechanism underlying synaptic plasticity deficits in NS mouse models?</p>
</sec>
<sec>
<title>Shp2 AND THE NMDA RECEPTOR</title>
<p>Glutamate is a major neurotransmitter in the central nervous system and its receptors play critical roles in regulating synaptic plasticity such as LTP and long-term depression (LTD) [<xref ref-type="bibr" rid="B34">34</xref><xref ref-type="bibr" rid="B35">35</xref><xref ref-type="bibr" rid="B36">36</xref><xref ref-type="bibr" rid="B42">42</xref>]. Among glutamate receptors (GluRs), N-methyl-D-aspartate (NMDA) receptors function as a coincidence detector which is crucial for the induction of LTP and LTD [<xref ref-type="bibr" rid="B34">34</xref>]. Accordingly, blocking NMDA receptors (NMDARs) impairs both synaptic plasticity and learning [<xref ref-type="bibr" rid="B43">43</xref><xref ref-type="bibr" rid="B44">44</xref><xref ref-type="bibr" rid="B45">45</xref>]. NMDARs interact with multiple proteins including protein kinases and phosphatases [<xref ref-type="bibr" rid="B46">46</xref>]. Shp2 has also been found to interact with GluN2B (Grin2b or NR2B) in mouse and rat brain [<xref ref-type="bibr" rid="B46">46</xref><xref ref-type="bibr" rid="B47">47</xref>]. Nerve ligation induced the expression of GluN2B, phosphorylation of GluN2B (p-GluN2B) at Y1472, as well as the interaction between PSD-95 and phosphorylated GluN2B (p-GluN2B) in rat dorsal horn [<xref ref-type="bibr" rid="B48">48</xref>]. Interestingly, the upregulation of GluN2B and its interaction with PSD-95 are blocked by Shp2 inhibition, suggesting that Shp2 is involved in regulating GluN2B phosphorylation and its interaction with PSD-95 [<xref ref-type="bibr" rid="B48">48</xref>]. Later, it was shown that BDNF treatment increases the phosphorylation of Shp2, as well as the interaction between Shp2 and GluN2B, in cortical neurons and spinal cord of rats [<xref ref-type="bibr" rid="B47">47</xref><xref ref-type="bibr" rid="B49">49</xref>]. By an as yet unknown mechanism, phosphorylated Shp2 enhances the functional expression of GluN2B and positively regulates LTP induction in rat spinal cord after spinal nerve ligation [<xref ref-type="bibr" rid="B49">49</xref>]. In addition, inhibiting Shp2 by siRNA or a pharmacological inhibitor blocks BDNF- or spinal nerve ligation-induced LTP, suggesting that Shp2 is required for GluN2B-dependent LTP in rat spinal cord [<xref ref-type="bibr" rid="B49">49</xref>].</p>
<p>Shp2 is also involved in regulating NMDAR function in the forebrain. Phosphorylation of GluN2A (Grin2a or NR2A) at Y1325 and GluN2B at Y1472, which are Src phosphorylation target sites, were increased in the hippocampus of Shp2 knockout (CaSKO) mice that showed reduced mEPSC frequency and impaired LTP in the hippocampus [<xref ref-type="bibr" rid="B39">39</xref>]. In the brain, Yan and colleagues showed that the synaptic expression or function of the zinc-sensitive GluN2A subunit of NMDAR was increased in pyramidal neurons of the hippocampal CA1 region in CaSKO mice, whereas the NMDAR/AMPAR current ratio in CaSKO mice was not different from that of wild type controls [<xref ref-type="bibr" rid="B39">39</xref>]. It remains unclear how the alteration in subunit composition of synaptic NMDAR leads to deficits in LTP in CaSKO mice, without affecting overall NMDAR currents in the hippocampus.</p>
<p>A recent study has shown that NMDAR function is altered in Shp2<sup>D61G/+</sup> mice [<xref ref-type="bibr" rid="B32">32</xref>]. Levy and colleagues found that NMDAR-, but not AMPAR-mediated, current is significantly reduced in the hippocampal neurons of Shp2<sup>D61G/+</sup> mice ([<xref ref-type="bibr" rid="B32">32</xref>]; but also see below). Specifically, Shp2 was found to directly dephosphorylate GluN2B Y1252, which interrupts the binding of GluN2B to the actin regulatory scaffolding protein Nck2 [<xref ref-type="bibr" rid="B32">32</xref>]. NMDAR-mediated current decayed faster in Shp2<sup>D61G/+</sup>mutants than in wild type littermates and NMDAR-current in Shp2<sup>D61G/+</sup> mice were insensitive to the GluN2B blocker ifenprodil, suggesting that GluN2B function is reduced in Shp2<sup>D61G/+</sup> mice [<xref ref-type="bibr" rid="B32">32</xref>]. These results might be inconsistent with the previous finding that Shp2 positively regulates NMDAR function in spinal cord [<xref ref-type="bibr" rid="B49">49</xref>]. In addition, surface expression of GluN2B was not reduced in mutant mice and it remains to be investigated how the direct dephosphorylation of GluN2B Y1252 by Shp2 reduces GluN2B function.</p>
</sec>
<sec>
<title>Shp2 AND THE AMPA RECEPTOR</title>
<p>In addition to NMDAR, Î±-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (AMPAR) is a subtype of ionotropic glutamate receptors which also plays critical roles in synaptic plasticity [<xref ref-type="bibr" rid="B50">50</xref><xref ref-type="bibr" rid="B51">51</xref>]. Regulations of the postsynaptic membrane trafficking of AMPAR are the primary mechanism for the expression of LTP and LTD [<xref ref-type="bibr" rid="B52">52</xref><xref ref-type="bibr" rid="B53">53</xref>]. Kinases and phosphatases, in general, bi-directionally regulate the synaptic plasticity (LTP <italic>vs.</italic> LTD) by either directly or indirectly regulating AMPAR trafficking [<xref ref-type="bibr" rid="B54">54</xref><xref ref-type="bibr" rid="B55">55</xref><xref ref-type="bibr" rid="B56">56</xref>]. Among phosphatases, protein phosphatase 1 (PP1) and calcineurin have been implicated in LTD induction [<xref ref-type="bibr" rid="B57">57</xref>]. Intriguingly, in contrast to the other phosphatases, recent studies strongly suggest that Shp2 is required for the synaptic delivery of AMPAR as well as LTP induction. LTP induction either by chemical or electrical stimulation increased Shp2 activity assessed by its Y542 phosphorylation, GluA1 (GluR1 or Gria1) phosphorylation at S845 and GluA1 surface expression in the hippocampal neurons [<xref ref-type="bibr" rid="B58">58</xref>]. A Shp2 inhibitor NSC87877 suppressed the phosphorylation of Shp2 as well as the phosphorylation and membrane trafficking of GluA1, suggesting that Shp2 positively regulates AMPAR trafficking during LTP induction [<xref ref-type="bibr" rid="B58">58</xref>]. Notably, MEK inhibitor U0126 treatment blocked LTP-induced phosphorylation of GluA1 S845 without affecting Shp2 phosphorylation, suggesting that ERK is a downstream of Shp2 [<xref ref-type="bibr" rid="B58">58</xref>]. More recently, it has been shown that Shp2 phosphatase activity is critically involved in regulating the phosphorylation of GluA1 at S845 and its surface expression during the TTX-mediated synaptic upscaling [<xref ref-type="bibr" rid="B59">59</xref>]. Since the prolonged TTX treatment was shown to decrease ERK1/2 activity [<xref ref-type="bibr" rid="B59">59</xref>], it is unlikely that Shp2 regulate GluA1 phosphorylation via Ras-Erk pathway. How Shp2 regulates GluA1 phosphorylation remains to be further investigated.</p>
<p>A NS associated mutant Shp2 (Shp2<sup>D61G</sup>) was also shown to increase AMPAR trafficking. Overexpressing Shp2<sup>D61G</sup> in fully matured cultured hippocampal neurons (DIV 21) significantly increased the number of the surface GluA1 clusters, which was blocked by inhibiting MAPK activity [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B60">60</xref>]. Consistently, the frequency of excitatory postsynaptic current (EPSC) and AMPA/NMDA current ratio were significantly higher in the hippocampal pyramidal neurons of both Shp2<sup>D61G/+</sup> knock-in mice and AAV-Shp2<sup>D61G</sup> expressing mice compared to the control groups, which were reversed by reducing MAPK activity [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B33">33</xref>]. Taken together, these results strongly suggest that Shp2 can facilitate the synaptic trafficking of GluA1 in the hippocampus. However, the mechanism of how Shp2 regulates the surface expression of GluA1 remains to be investigated.</p>
</sec>
<sec>
<title>PERSPECTIVES</title>
<p>We reviewed that Shp2 is involved in regulating glutamate receptors. However, it is still not clear how Shp2 regulates glutamate receptors. Shp2 may have both <italic>direct</italic> and <italic>indirect</italic> role in regulating the function and expression of glutamate receptors (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Considering that Shp2 is generally acting as a positive regulator of the RAS-ERK pathway, Shp2 may indirectly facilitate AMPAR synaptic trafficking through activating the RAS-ERK pathway. The activation of the RAS-ERK pathway has been shown to facilitate AMPAR trafficking to the synaptic membrane [<xref ref-type="bibr" rid="B61">61</xref>]. For example, expressing a constitutively active RAS mutant enhanced the surface expression of AMPAR [<xref ref-type="bibr" rid="B62">62</xref>]. Inhibiting Shp2 by NSC87877 treatment blocked both ERK phosphorylation and AMPAR trafficking during chemical LTP induction in hippocampal cultures [<xref ref-type="bibr" rid="B58">58</xref>]. The Shp2<sup>D61G</sup> mutant enhanced AMPAR-mediated current in the hippocampus, which was fully reversed by MEK inhibitor SL327 treatment [<xref ref-type="bibr" rid="B31">31</xref>], suggesting that there is a strong correlation between Shp2, ERK, and AMPAR trafficking.</p>
<p>In addition to the suggested role of Shp2 in facilitating AMPAR trafficking via ERK activation, Levy and colleagues showed that Shp2 directly dephosphorylates GluN2B at Y1252 without affecting the phosphorylation at Y1472 or Y1336, in both <italic>in vitro</italic> and <italic>ex vivo</italic> conditions [<xref ref-type="bibr" rid="B32">32</xref>]. This direct dephosphorylation of GluN2B at Y1472 reduces the localization of the scaffolding protein Nck2 to dendritic spines and contributes to the reduction of GluN1-GluN2B mediated currents without affecting AMPAR-mediated currents [<xref ref-type="bibr" rid="B32">32</xref>]. However, it is still controversial whether Shp2 directly regulates NMDAR function in the hippocampus. As reviewed above, AMPAR, but not NMDAR expression or function, was increased in the adult hippocampus or mature hippocampal cultures expressing Shp2<sup>D61G</sup> [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B60">60</xref>]. Interestingly, the mutant Shp2<sup>D61G</sup> was shown to differentially regulate AMPAR and NMDAR surface expression depending on developmental maturation [<xref ref-type="bibr" rid="B60">60</xref>]. Expressing Shp2<sup>D61G</sup> in premature hippocampal neurons (DIV 6) only increased the surface expression of the GluN1 subunit of NMDAR without affecting AMPAR, whereas expressing Shp2<sup>D61G</sup> in mature neurons (&gt; DIV 12) increased GluA1 expression without affecting GluN1 expression [<xref ref-type="bibr" rid="B60">60</xref>]. These age-dependent distinct roles of Shp2 in glutamate receptor trafficking may underlie the seemingly contradictory findings (increased vs. decreased AMPA/NMDA currents in Shp2<sup>D61G/+</sup> mice) from different laboratories [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B32">32</xref>]. In addition, the difference in genetic backgrounds of the mice (mixed C57BL/6J and 129/SvJ background vs. 129S6/SvEv) might also have contributed to the distinct phenotypes [<xref ref-type="bibr" rid="B31">31</xref><xref ref-type="bibr" rid="B32">32</xref>].</p>
<p>There are also inconsistent results on the role of Shp2 on GluN2B Y1472. Peng and colleagues [<xref ref-type="bibr" rid="B48">48</xref>] showed Shp2 activity was required for the phosphorylation of GluN2B at Y1472 in rat dorsal horn after nerve ligation by an unknown mechanism. However, in the forebrain, GluN2B Y1472 phosphorylation was significantly increased in Shp2 knockout mice [<xref ref-type="bibr" rid="B39">39</xref>]. The increased GluN2B Y1472 phosphorylation was reversed by a Src family kinase inhibitor, suggesting that Shp2 may negatively regulate GluN2B Y1472 phosphorylation through suppressing Src activity [<xref ref-type="bibr" rid="B39">39</xref>]. This result is interesting because previous studies have shown that Shp2 is involved in activating Src family kinases including Src [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B63">63</xref><xref ref-type="bibr" rid="B64">64</xref>]. Differences in tissue or cell type (dorsal horn vs. forebrain or fibroblast vs. neurons) may be responsible for these contradictory results. Indeed, it has been shown that the impacts of Shp2 mutation have cell type and context-specificity [<xref ref-type="bibr" rid="B18">18</xref><xref ref-type="bibr" rid="B30">30</xref><xref ref-type="bibr" rid="B33">33</xref><xref ref-type="bibr" rid="B39">39</xref><xref ref-type="bibr" rid="B64">64</xref>]. Recently, Ryu and colleagues showed that the SHP2<sup>D61G</sup> mutant increases Ras-Erk activation only in excitatory, but not in inhibitory, neurons in adult mouse hippocampus [<xref ref-type="bibr" rid="B33">33</xref>]. Therefore, it is plausible to argue that Shp2 may recruit distinct downstream signaling pathways to regulate the function and expression of glutamate receptors in a cell type- and age-specific manner. Understanding the cell type-specific role of SHP2 is critical when developing treatments for SHP2-associated disorders such as NS and LEOPARD syndrome, since SHP2 is ubiquitously expressed in the brain [<xref ref-type="bibr" rid="B38">38</xref><xref ref-type="bibr" rid="B65">65</xref><xref ref-type="bibr" rid="B66">66</xref>]. Advances in single cell biology such as single cell genomics combined with either whole cell patch clamp recording or state-of-the-art imaging techniques using molecular sensors for Shp2, Erk, or glutamate receptors will be useful in answering these remaining questions.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>This study was supported by grants to Y.-S.L. (NRF-2019R1A2C1084232 and NRF-2019R1A4A2001609) and to H.-H.R. (NRF-2019R1A6A3A01097089) from the National Research Foundation of Korea.</p>
</ack>
<fn-group>
<fn fn-type="con">
<p><bold>Author contributions:</bold> Y.-S.L. conceptualized the study. H.-H.R., S.Y.K., and Y.-S.L. wrote the manuscript. H.-H.R. prepared the figure. H.-H.R. and Y.-S.L. edited the final version of the manuscript.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>CONFLICTS OF INTEREST:</bold> The authors declare no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jamieson</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>van Reen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elsawi</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Hol</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mariman</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Mapping a gene for Noonan syndrome to the long arm of chromosome 12</article-title>
<source/>Nat Genet
          <year>1994</year>
<volume>8</volume>
<fpage>357</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">7894486</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Banville</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1993</year>
<volume>90</volume>
<fpage>2197</fpage>
<lpage>2201</lpage>
<pub-id pub-id-type="pmid">7681589</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hof</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pluskey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dhe-Paganon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eck</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Shoelson</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Crystal structure of the tyrosine phosphatase SHP-2</article-title>
<source/>Cell
          <year>1998</year>
<volume>92</volume>
<fpage>441</fpage>
<lpage>450</lpage>
<pub-id pub-id-type="pmid">9491886</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2</article-title>
<source/>Structure
          <year>1998</year>
<volume>6</volume>
<fpage>249</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="pmid">9551546</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The âShpâing news: SH2 domain-containing tyrosine phosphatases in cell signaling</article-title>
<source/>Trends Biochem Sci
          <year>2003</year>
<volume>28</volume>
<fpage>284</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">12826400</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tajan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Rocca Serra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Edouard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yart</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>SHP2 sails from physiology to pathology</article-title>
<source/>Eur J Med Genet
          <year>2015</year>
<volume>58</volume>
<fpage>509</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="pmid">26341048</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>41677</fpage>
<lpage>41684</lpage>
<pub-id pub-id-type="pmid">12923167</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dance</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montagner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Salles</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Yart</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raynal</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway</article-title>
<source/>Cell Signal
          <year>2008</year>
<volume>20</volume>
<fpage>453</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">17993263</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity</article-title>
<source/>Mol Cell Biol
          <year>2000</year>
<volume>20</volume>
<fpage>1526</fpage>
<lpage>1536</lpage>
<pub-id pub-id-type="pmid">10669730</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kontaridis</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>David</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Barford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects</article-title>
<source/>J Biol Chem
          <year>2006</year>
<volume>281</volume>
<fpage>6785</fpage>
<lpage>6792</lpage>
<pub-id pub-id-type="pmid">16377799</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marin</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Keith</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Guha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kalaitzidis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lauriol</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Franchini</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Kontaridis</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation</article-title>
<source/>J Clin Invest
          <year>2011</year>
<volume>121</volume>
<fpage>1026</fpage>
<lpage>1043</lpage>
<pub-id pub-id-type="pmid">21339643</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paardekooper Overman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tessadori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>NoÃ«l</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bakkers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>den Hertog</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish</article-title>
<source/>Development
          <year>2014</year>
<volume>141</volume>
<fpage>1961</fpage>
<lpage>1970</lpage>
<pub-id pub-id-type="pmid">24718990</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvajal-Vergara</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sevilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D'Souza</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Schaniel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Rozov</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Edelmann</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Waghray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lichtenbelt</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patient-specific induced pluripotent stemcell-derived models of LEOPARD syndrome</article-title>
<source/>Nature
          <year>2010</year>
<volume>465</volume>
<fpage>808</fpage>
<lpage>812</lpage>
<pub-id pub-id-type="pmid">20535210</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edouard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Montagner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dance</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Conte</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yart</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parfait</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tauber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Salles</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Raynal</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?</article-title>
<source/>Cell Mol Life Sci
          <year>2007</year>
<volume>64</volume>
<fpage>1585</fpage>
<lpage>1590</lpage>
<pub-id pub-id-type="pmid">17453145</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoder</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis</article-title>
<source/>Blood
          <year>2003</year>
<volume>102</volume>
<fpage>2074</fpage>
<lpage>2080</lpage>
<pub-id pub-id-type="pmid">12791646</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivins Zito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kontaridis</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Fornaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis</article-title>
<source/>J Cell Physiol
          <year>2004</year>
<volume>199</volume>
<fpage>227</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="pmid">15040005</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway</article-title>
<source/>Mol Cell Biol
          <year>1999</year>
<volume>19</volume>
<fpage>2416</fpage>
<lpage>2424</lpage>
<pub-id pub-id-type="pmid">10022928</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mohi</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ismat</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Kutok</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Gilliland</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</article-title>
<source/>Nat Med
          <year>2004</year>
<volume>10</volume>
<fpage>849</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="pmid">15273746</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ash</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kee</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ure</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ito-Ishida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arenkiel</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Smirnakis</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>HY</given-names>
</name>
</person-group>
<article-title>Loss and gain of MeCP2 cause similar hippocampal circuit dysfunction that is rescued by deep brain stimulation in a rett syndrome mouse model</article-title>
<source/>Neuron
          <year>2016</year>
<volume>91</volume>
<fpage>739</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="pmid">27499081</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Noonan syndrome and related disorders: genetics and pathogenesis</article-title>
<source/>Annu Rev Genomics Hum Genet
          <year>2005</year>
<volume>6</volume>
<fpage>45</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">16124853</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romano</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Allanson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Dahlgren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pierpont</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Takemoto</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Noonan syndrome: clinical features, diagnosis, and management guidelines</article-title>
<source/>Pediatrics
          <year>2010</year>
<volume>126</volume>
<fpage>746</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="pmid">20876176</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adviento</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Corbin</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Widjaja</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Desachy</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Enrique</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Risi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marco</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Hendren</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Autism traits in the RASopathies</article-title>
<source/>J Med Genet
          <year>2014</year>
<volume>51</volume>
<fpage>10</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">24101678</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Portnoy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Psychological profile of children with Noonan syndrome</article-title>
<source/>Dev Med Child Neurol
          <year>2005</year>
<volume>47</volume>
<fpage>35</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">15686287</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierpont</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Tworog-Dube</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Learning and memory in children with Noonan syndrome</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<fpage>2250</fpage>
<lpage>2257</lpage>
<pub-id pub-id-type="pmid">23918208</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jindal</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Burdine</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Shvartsman</surname>
<given-names>SY</given-names>
</name>
</person-group>
<article-title>RASopathies: unraveling mechanisms with animal models</article-title>
<source/>Dis Model Mech
          <year>2015</year>
<volume>8</volume>
<fpage>1167</fpage>
<pub-id pub-id-type="pmid">26398161</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bale</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Abel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Akil</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Carlezon</surname>
<given-names>WA</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Ressler</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The critical importance of basic animal research for neuropsychiatric disorders</article-title>
<source/>Neuropsychopharmacology
          <year>2019</year>
<volume>44</volume>
<fpage>1349</fpage>
<lpage>1353</lpage>
<pub-id pub-id-type="pmid">31048727</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howe</surname>
<given-names>JR</given-names>
<suffix>6th</suffix>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Golshani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mucke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The mouse as a model for neuropsychiatric drug development</article-title>
<source/>Curr Biol
          <year>2018</year>
<volume>28</volume>
<fpage>R909</fpage>
<lpage>R914</lpage>
<pub-id pub-id-type="pmid">30205056</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagani</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The phosphatase SHP2 regulates the spacing effect for long-term memory induction</article-title>
<source/>Cell
          <year>2009</year>
<volume>139</volume>
<fpage>186</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">19804763</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tajan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paccoud</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Branka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Edouard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yart</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The RASopathy family: consequences of germline activation of the RAS/MAPK pathway</article-title>
<source/>Endocr Rev
          <year>2018</year>
<volume>39</volume>
<fpage>676</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="pmid">29924299</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Newbigging</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<fpage>4736</fpage>
<lpage>4741</lpage>
<pub-id pub-id-type="pmid">19251646</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Butz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Balaji</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Kaang</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<fpage>1736</fpage>
<lpage>1743</lpage>
<pub-id pub-id-type="pmid">25383899</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Sudarsana Devi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Katrancha</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Greer</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Machida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koleske</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Noonan syndrome-associated SHP2 dephosphorylates GluN2B to regulate NMDA receptor function</article-title>
<source/>Cell Rep
          <year>2018</year>
<volume>24</volume>
<fpage>1523</fpage>
<lpage>1535</lpage>
<pub-id pub-id-type="pmid">30089263</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kaang</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
</person-group>
<article-title>Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory</article-title>
<source/>Sci Signal
          <year>2019</year>
<volume>12</volume>
<elocation-id>eaau5755</elocation-id>
<pub-id pub-id-type="pmid">30837304</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Synaptic plasticity: LTP and LTD</article-title>
<source/>Curr Opin Neurobiol
          <year>1994</year>
<volume>4</volume>
<fpage>389</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="pmid">7919934</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>The cell biology of synaptic plasticity</article-title>
<source/>Science
          <year>2011</year>
<volume>334</volume>
<fpage>623</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">22053042</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The molecular and cellular biology of enhanced cognition</article-title>
<source/>Nat Rev Neurosci
          <year>2009</year>
<volume>10</volume>
<fpage>126</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">19153576</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neves</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Bliss</surname>
<given-names>TV</given-names>
</name>
</person-group>
<article-title>Synaptic plasticity, memory and the hippocampus: a neural network approach to causality</article-title>
<source/>Nat Rev Neurosci
          <year>2008</year>
<volume>9</volume>
<fpage>65</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">18094707</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kusakari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Saitow</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ago</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shibasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sato-Hashimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsuzaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kotani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matozaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Shp2 in forebrain neurons regulates synaptic plasticity, locomotion, and memory formation in mice</article-title>
<source/>Mol Cell Biol
          <year>2015</year>
<volume>35</volume>
<fpage>1557</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="pmid">25713104</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Increased Src Family kinase activity disrupts excitatory synaptic transmission and impairs remote fear memory in forebrain Shp2-Deficient mice</article-title>
<source/>Mol Neurobiol
          <year>2017</year>
<volume>54</volume>
<fpage>7235</fpage>
<lpage>7250</lpage>
<pub-id pub-id-type="pmid">27796759</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fornaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth</article-title>
<source/>J Cell Biol
          <year>2006</year>
<volume>175</volume>
<fpage>87</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">17015617</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Chapeau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hagihara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<fpage>16064</fpage>
<lpage>16069</lpage>
<pub-id pub-id-type="pmid">15520383</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LÃ¼scher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nicoll</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Synaptic plasticity and dynamic modulation of the postsynaptic membrane</article-title>
<source/>Nat Neurosci
          <year>2000</year>
<volume>3</volume>
<fpage>545</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="pmid">10816309</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butcher</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>A dose-related impairment of spatial learning by the NMDA receptor antagonist, 2-amino-5-phosphonovalerate (AP5)</article-title>
<source/>Eur Neuropsychopharmacol
          <year>1990</year>
<volume>1</volume>
<fpage>15</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">1983778</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP <italic>in vivo</italic> at intracerebral concentrations comparable to those that block LTP <italic>in vitro</italic></article-title>
<source/>J Neurosci
          <year>1992</year>
<volume>12</volume>
<fpage>21</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">1345945</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsien</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Huerta</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory</article-title>
<source/>Cell
          <year>1996</year>
<volume>87</volume>
<fpage>1327</fpage>
<lpage>1338</lpage>
<pub-id pub-id-type="pmid">8980238</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Husi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Blackstock</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of NMDA receptor-adhesion protein signaling complexes</article-title>
<source/>Nat Neurosci
          <year>2000</year>
<volume>3</volume>
<fpage>661</fpage>
<lpage>669</lpage>
<pub-id pub-id-type="pmid">10862698</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Len</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Suen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Mount</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>IB</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor enhances association of protein tyrosine phosphatase PTP1D with the NMDA receptor subunit NR2B in the cortical postsynaptic density</article-title>
<source/>Brain Res Mol Brain Res
          <year>1999</year>
<volume>70</volume>
<fpage>18</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">10381539</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>TB</given-names>
</name>
</person-group>
<article-title>Spinal SIRPÎ±1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats</article-title>
<source/>Pain
          <year>2012</year>
<volume>153</volume>
<fpage>1042</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="pmid">22425446</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>XD</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation</article-title>
<source/>Neurobiol Dis
          <year>2015</year>
<volume>73</volume>
<fpage>428</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">25447233</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zukin</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity</article-title>
<source/>Trends Neurosci
          <year>2002</year>
<volume>25</volume>
<fpage>571</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="pmid">12392932</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isaac</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Ashby</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>McBain</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity</article-title>
<source/>Neuron
          <year>2007</year>
<volume>54</volume>
<fpage>859</fpage>
<lpage>871</lpage>
<pub-id pub-id-type="pmid">17582328</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huganir</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Nicoll</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>AMPARs and synaptic plasticity: the last 25 years</article-title>
<source/>Neuron
          <year>2013</year>
<volume>80</volume>
<fpage>704</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="pmid">24183021</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diering</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Huganir</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>The AMPA receptor code of synaptic plasticity</article-title>
<source/>Neuron
          <year>2018</year>
<volume>100</volume>
<fpage>314</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">30359599</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Barbarosie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kameyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Huganir</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity</article-title>
<source/>Nature
          <year>2000</year>
<volume>405</volume>
<fpage>955</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">10879537</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kameyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Huganir</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Involvement of a postsynaptic protein kinase A substrate in the expression of homosynaptic long-term depression</article-title>
<source/>Neuron
          <year>1998</year>
<volume>21</volume>
<fpage>1163</fpage>
<lpage>1175</lpage>
<pub-id pub-id-type="pmid">9856471</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barria</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Derkach</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Soderling</surname>
<given-names>TR</given-names>
</name>
</person-group>
<article-title>Regulatory phosphorylation of AMPA-type glutamate receptors by CaMKII during long-term potentiation</article-title>
<source/>Science
          <year>1997</year>
<volume>276</volume>
<fpage>2042</fpage>
<lpage>2045</lpage>
<pub-id pub-id-type="pmid">9197267</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulkey</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Herron</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>An essential role for protein phosphatases in hippocampal long-term depression</article-title>
<source/>Science
          <year>1993</year>
<volume>261</volume>
<fpage>1051</fpage>
<lpage>1055</lpage>
<pub-id pub-id-type="pmid">8394601</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Increased activity of Src homology 2 domain containing phosphotyrosine phosphatase 2 (Shp2) regulates activity-dependent AMPA receptor trafficking</article-title>
<source/>J Biol Chem
          <year>2016</year>
<volume>291</volume>
<fpage>18856</fpage>
<lpage>18866</lpage>
<pub-id pub-id-type="pmid">27417137</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Src homology 2 domain-containing phosphotyrosine phosphatase 2 (Shp2) controls surface GluA1 protein in synaptic homeostasis</article-title>
<source/>J Biol Chem
          <year>2017</year>
<volume>292</volume>
<fpage>15481</fpage>
<lpage>15488</lpage>
<pub-id pub-id-type="pmid">28768764</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Rhee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Noonan syndrome-associated SHP2 mutation differentially modulates the expression of postsynaptic receptors according to developmental maturation</article-title>
<source/>Neurosci Lett
          <year>2017</year>
<volume>649</volume>
<fpage>41</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">28366775</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stornetta</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Ras and Rap signaling in synaptic plasticity and mental disorders</article-title>
<source/>Neuroscientist
          <year>2011</year>
<volume>17</volume>
<fpage>54</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">20431046</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Van Aelst</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malinow</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Ras and Rap control AMPA receptor trafficking during synaptic plasticity</article-title>
<source/>Cell
          <year>2002</year>
<volume>110</volume>
<fpage>443</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">12202034</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohnishi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okazawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Matozaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Src family kinases: modulators of neurotransmitter receptor function and behavior</article-title>
<source/>Trends Neurosci
          <year>2011</year>
<volume>34</volume>
<fpage>629</fpage>
<lpage>637</lpage>
<pub-id pub-id-type="pmid">22051158</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>SQ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kontaridis</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Bivona</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Schraven</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment</article-title>
<source/>Mol Cell
          <year>2004</year>
<volume>13</volume>
<fpage>341</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="pmid">14967142</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matozaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasuga</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Localization and subcellular distribution of SH-PTP2, a protein-tyrosine phosphatase with Src homology-2 domains, in rat brain</article-title>
<source/>Biochem Biophys Res Commun
          <year>1995</year>
<volume>211</volume>
<fpage>950</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">7598727</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servidei</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bhide</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Moskowitz</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Harsh</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes</article-title>
<source/>Neuroscience
          <year>1998</year>
<volume>82</volume>
<fpage>529</fpage>
<lpage>543</lpage>
<pub-id pub-id-type="pmid">9466459</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Fig. 1</label>
<caption>
<title>Graphical summary of the roles of Shp2 in regulating glutamate receptor function in the nervous system.</title>
<p>Shp2 is involved in regulating the phosphorylation of GluN2A at Y1325 and GluN2B at Y1252 and Y1472. Src positively regulates the phosphorylation of GluN2A at Y1325 and GluN2B at Y1472. In the forebrain, the activation of Src is negatively regulated by Shp2 [<xref ref-type="bibr" rid="B39">39</xref>]. Therefore, Shp2 has a negative effect on N-methyl-D-aspartate receptor (NMDAR) activation through suppressing Src activity in the forebrain. However, in the dorsal horn, Shp2 was shown to positively regulate the phosphorylation of GluN2B at Y1472 and interaction between GluN2B and PSD95 [<xref ref-type="bibr" rid="B48">48</xref>]. In contrast, the phosphorylation of GluN2B at Y1252 and binding to Nck2 are decreased in juvenile Shp2<sup>D61G/+</sup> knock-in mice, suggesting that Shp2 negatively regulates the phosphorylation of GluN2B at 1252 [<xref ref-type="bibr" rid="B32">32</xref>]. In adult mice, Shp2 promotes the surface expression of Î±-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) [<xref ref-type="bibr" rid="B31">31</xref>]. The red and green circles represent negative and positive regulation between NMDAR and its interaction partners (Nck2 and PSD95), respectively. The dashed lines indicate controversial results [<xref ref-type="bibr" rid="B39">39</xref><xref ref-type="bibr" rid="B64">64</xref>].</p>
</caption>
<graphic xlink:href="kjpp-24-129-g001"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>